OKI-006

• UNSPSC Description:

  OKI-006 is a potent and orally active inhibitor of histone deacetylase (HDAC). OKI-006 is a unique congener of the natural product HDAC inhibitor largazole. Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. OKI-006 has the potential for the research of cancer disease[1].

• Target Antigen:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/oki-006.html

• Solubility:

  10 mM in DMSO

• Smiles:

  SCC/C=C/[C@@H]1CC(NCC2=NC(C(NC(C)(C(N[C@H](C(O1)=O)C(C)C)=O)C)=O)=CS2)=O

• Molecular Weight:

  482.62

• References & Citations:

  [1]Diamond JR, et al. Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. Mol Cancer Ther. 2022;21(3):397-406.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1315334-23-6